fluoxetine has been researched along with Affective Disorders in 42 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A combination of the antipsychotic olanzapine and the serotonin reuptake inhibitor fluoxetine has been investigated in both bipolar depression and other affective disorders such as psychotic depression and treatment-refractory depression." | 8.83 | Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review. ( Owen, RT, 2006) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 5.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Fluoxetine monotherapy is an established treatment for pediatric mood disorders; however its efficacy in ADHD and comorbid mood disorder is unknown." | 5.34 | Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. ( Butterbaugh, GJ; Layman, AK; Purnell, W; Quintana, H, 2007) |
| "To evaluate the efficacy and feasibility of treating older people suffering from depression and/or phobic anxiety in the community with fluoxetine alone." | 5.09 | Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial. ( Katona, C; Livingston, G; Manela, M; Stevens, T; Watkin, V, 1999) |
| " A combination of the antipsychotic olanzapine and the serotonin reuptake inhibitor fluoxetine has been investigated in both bipolar depression and other affective disorders such as psychotic depression and treatment-refractory depression." | 4.83 | Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review. ( Owen, RT, 2006) |
| " However, MS mice treated with fluoxetine for 4 weeks after MS did not exhibit augmentation of allodynia, and their emotional response was attenuated." | 3.91 | Maternal separation as a risk factor for aggravation of neuropathic pain in later life in mice. ( Fukumoto, K; Jin, S; Mizoguchi, H; Sakamoto, G; Sato, J; Suzumura, A; Toyama, A; Wang, T, 2019) |
| "We report nine cases where fluoxetine (FX) (20 mg/day) was added to maintenance treatment with methadone (MTD) (dose range: 30-100 mg) in addicts with affective disorders." | 3.69 | Fluoxetine addition to methadone in addicts: pharmacokinetic aspects. ( Baumann, P; Bertschy, G; Eap, CB; Powell, K, 1996) |
| "Seventy-two major depressive disorder (MDD) subjects were treated with fluoxetine 20 mg (n = 13), venlafaxine 150 mg (n = 24), or placebo (n = 35) under double-blind conditions." | 2.75 | Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. ( Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF, 2010) |
| "To evaluate premenstrual daily dosing with fluoxetine for treatment of premenstrual dysphoric disorder." | 2.70 | Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries. ( Brown, EW; Cohen, LS; Freeman, E; Halbreich, U; McCray, S; Miner, C; Sundell, K, 2002) |
| " This study examined international dosage differences in antidepressant clinical trials, using a database formed and maintained as a component of a Cochrane review of comparative clinical trials of fluoxetine." | 2.43 | International dosage differences in fluoxetine clinical trials. ( Barbui, C; Brambilla, P; Cipriani, A; Nosè, M; Patten, S, 2005) |
| "Objectives Depression is tightly associated with cardiovascular comorbidity and accounts for high financial and social burden worldwide." | 1.46 | Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine. ( Amiri, S; Anoush, M; Bergen, H; Haj-Mirzaian, A; Hosseini, MJ; Jafarian, I; Rahimi-Balaei, M; Sonei, N, 2017) |
| "Patients with major depressive disorder (DSM-IV) who showed favorable treatment response to venlafaxine (mean +/- SD dose = 116." | 1.35 | Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. ( Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS, 2008) |
| "Fluoxetine monotherapy is an established treatment for pediatric mood disorders; however its efficacy in ADHD and comorbid mood disorder is unknown." | 1.34 | Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents. ( Butterbaugh, GJ; Layman, AK; Purnell, W; Quintana, H, 2007) |
| " Reduction of the fluoxetine dosage to 10 mg twice weekly was associated with the attainment of euthymia in 18 days." | 1.31 | Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania. ( Devitt, PJ; Megna, JL, 2001) |
| "Mood disorders are the leading causes of morbidity and mortality in children and adolescence." | 1.31 | Mood disorders in children and adolescents: psychopharmacological treatment. ( Emslie, GJ; Mayes, TL, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 13 (30.95) | 18.2507 |
| 2000's | 18 (42.86) | 29.6817 |
| 2010's | 10 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Todorović, N | 1 |
| Filipović, D | 1 |
| Mizoguchi, H | 1 |
| Fukumoto, K | 1 |
| Sakamoto, G | 1 |
| Jin, S | 1 |
| Toyama, A | 1 |
| Wang, T | 1 |
| Suzumura, A | 1 |
| Sato, J | 1 |
| Miller, MC | 1 |
| Boldrini, M | 1 |
| Butt, TH | 1 |
| Santiago, AN | 1 |
| Tamir, H | 1 |
| Dwork, AJ | 1 |
| Rosoklija, GB | 1 |
| Arango, V | 1 |
| Hen, R | 1 |
| Mann, JJ | 1 |
| Amodeo, LR | 1 |
| Greenfield, VY | 1 |
| Humphrey, DE | 1 |
| Varela, V | 1 |
| Pipkin, JA | 1 |
| Eaton, SE | 1 |
| Johnson, JD | 1 |
| Plant, CP | 1 |
| Harmony, ZR | 1 |
| Wang, L | 1 |
| Crawford, CA | 1 |
| Sonei, N | 1 |
| Amiri, S | 1 |
| Jafarian, I | 1 |
| Anoush, M | 1 |
| Rahimi-Balaei, M | 1 |
| Bergen, H | 1 |
| Haj-Mirzaian, A | 1 |
| Hosseini, MJ | 1 |
| Demchuk, ND | 1 |
| Shutov, AA | 1 |
| Pinna, G | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| McHugh, PC | 1 |
| Joyce, PR | 2 |
| Deng, X | 1 |
| Kennedy, MA | 1 |
| Hunter, AM | 1 |
| Leuchter, AF | 1 |
| Cook, IA | 1 |
| Abrams, M | 1 |
| Krzyzosiak, A | 1 |
| Szyszka-Niagolov, M | 1 |
| Wietrzych, M | 1 |
| Gobaille, S | 1 |
| Muramatsu, S | 1 |
| Krezel, W | 1 |
| Ziv, L | 1 |
| Muto, A | 1 |
| Schoonheim, PJ | 1 |
| Meijsing, SH | 1 |
| Strasser, D | 1 |
| Ingraham, HA | 1 |
| Schaaf, MJ | 1 |
| Yamamoto, KR | 1 |
| Baier, H | 1 |
| Cohen, LS | 2 |
| Miner, C | 1 |
| Brown, EW | 1 |
| Freeman, E | 1 |
| Halbreich, U | 1 |
| Sundell, K | 1 |
| McCray, S | 1 |
| Lustman, PJ | 1 |
| Clouse, RE | 1 |
| Shelton, RC | 1 |
| Yeragani, VK | 1 |
| Pohl, R | 1 |
| Mallavarapu, M | 1 |
| Balon, R | 1 |
| Patten, S | 1 |
| Cipriani, A | 1 |
| Brambilla, P | 1 |
| Nosè, M | 1 |
| Barbui, C | 1 |
| Carrasco, JL | 1 |
| Sandner, C | 1 |
| Owen, RT | 1 |
| Quintana, H | 1 |
| Butterbaugh, GJ | 1 |
| Purnell, W | 1 |
| Layman, AK | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Lin, CH | 1 |
| Lin, KS | 1 |
| Lin, CY | 1 |
| Chen, MC | 1 |
| Lane, HY | 1 |
| Rubinow, DR | 1 |
| Schmidt, PJ | 1 |
| Bertschy, G | 2 |
| Baumann, P | 2 |
| Menys, VC | 1 |
| Smith, CC | 1 |
| Lewins, P | 1 |
| Farmer, RD | 1 |
| Noble, MI | 1 |
| Eap, CB | 1 |
| Powell, K | 1 |
| Sovner, R | 1 |
| Stone, A | 1 |
| Fox, C | 1 |
| Rosenbaum, JF | 1 |
| Coccaro, EF | 1 |
| Kavoussi, RJ | 1 |
| Hauger, RL | 1 |
| Steiner, M | 1 |
| Lamont, J | 1 |
| Steinberg, S | 1 |
| Stewart, D | 1 |
| Reid, R | 1 |
| Streiner, D | 1 |
| Labbate, LA | 1 |
| Grimes, JB | 1 |
| Hines, A | 1 |
| Pollack, MH | 1 |
| Brown, KW | 1 |
| Sloan, RL | 1 |
| Pentland, B | 1 |
| Stevens, T | 1 |
| Katona, C | 1 |
| Manela, M | 1 |
| Watkin, V | 1 |
| Livingston, G | 1 |
| Nurnberg, HG | 1 |
| Thompson, PM | 1 |
| Hensley, PL | 1 |
| McCullagh, S | 1 |
| Feinstein, A | 1 |
| Gendall, KA | 1 |
| Mulder, RT | 1 |
| Sullivan, PF | 1 |
| Megna, JL | 1 |
| Devitt, PJ | 1 |
| Emslie, GJ | 1 |
| Mayes, TL | 1 |
| Parry, BL | 1 |
| Newton, RP | 1 |
| Lin, J | 1 |
| Thompson, DS | 1 |
| Weisberger, AM | 1 |
| Telner, J | 1 |
| Surphlis, W | 1 |
| Lapierre, Y | 1 |
| Mehta, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for fluoxetine and Affective Disorders
| Article | Year |
|---|---|
SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake.
Topics: Animals; Brain; Fluoxetine; gamma-Aminobutyric Acid; Humans; Mental Disorders; Mood Disorders; Pregn | 2009 |
Treatment of depression in diabetes: impact on mood and medical outcome.
Topics: Behavior Therapy; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Diabetes Mellitus; Flu | 2002 |
The combination of olanzapine and fluoxetine in mood disorders.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Com | 2003 |
International dosage differences in fluoxetine clinical trials.
Topics: Drug Administration Schedule; Drug Prescriptions; Europe; Fluoxetine; Humans; Mood Disorders; Random | 2005 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorder | 2005 |
Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
Ring chromosome 22 and mood disorders.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Child; Chromosomes, Human, Pair 22; Drug Therapy, Com | 1996 |
Chronobiological basis of female-specific mood disorders.
Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P | 2001 |
Treating premenstrual dysphoric disorder using serotonin agents.
Topics: Female; Fluoxetine; Humans; Mood Disorders; Premenstrual Syndrome; Selective Serotonin Reuptake Inhi | 2001 |
12 trials available for fluoxetine and Affective Disorders
| Article | Year |
|---|---|
[Correction of motor and affective symptoms of parkinsonism by selective serotonine reuptake inhibition antidepressant].
Topics: Adult; Aged; Female; Fluoxetine; Humans; Male; Middle Aged; Mood Disorders; Parkinson Disease; Psych | 2008 |
Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain; | 2010 |
Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.
Topics: Diagnosis, Computer-Assisted; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 2002 |
Approximate entropy of symptoms of mood: an effective technique to quantify regularity of mood.
Topics: Adult; Central Nervous System Stimulants; Double-Blind Method; Female; Fluoxetine; Humans; Male; Moo | 2003 |
Serotonin function and antiaggressive response to fluoxetine: a pilot study.
Topics: Adolescent; Adolescent Behavior; Adult; Aggression; Double-Blind Method; Fenfluramine; Fluoxetine; H | 1997 |
Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria.
Topics: Adult; Female; Fluoxetine; Humans; Menstrual Cycle; Middle Aged; Mood Disorders; Premenstrual Syndro | 1997 |
Fluoxetine as a treatment for post-stroke emotionalism.
Topics: Aged; Antidepressive Agents; Cerebral Infarction; Double-Blind Method; Female; Fluoxetine; Humans; M | 1998 |
Drug treatment of older people with affective disorders in the community: lessons from an attempted clinical trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disorders; Clinical Trial | 1999 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Sc | 1999 |
The effects of fluoxetine versus nortriptyline on body weight in depression.
Topics: Adrenergic Uptake Inhibitors; Body Weight; Female; Fluoxetine; Humans; Male; Mood Disorders; Nortrip | 2000 |
Chronobiological basis of female-specific mood disorders.
Topics: Antidepressive Agents, Second-Generation; Chronobiology Phenomena; Cross-Over Studies; Depression, P | 2001 |
Effects of antidepressants on thinking styles in depressed inpatients.
Topics: Adult; Antidepressive Agents; Clinical Trials as Topic; Cognition; Female; Fluoxetine; Humans; Imipr | 1988 |
22 other studies available for fluoxetine and Affective Disorders
| Article | Year |
|---|---|
Prefrontal cortical glutathione-dependent defense and proinflammatory mediators in chronically isolated rats: Modulation by fluoxetine or clozapine.
Topics: Animals; Antidepressive Agents; Clozapine; Cytokines; Defense Mechanisms; Disease Models, Animal; Fl | 2017 |
Maternal separation as a risk factor for aggravation of neuropathic pain in later life in mice.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Calcium-Binding Proteins; Disea | 2019 |
When depression doesn't lead with depression.
Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fl | 2013 |
Benzodiazepines and the potential trophic effect of antidepressants on dentate gyrus cells in mood disorders.
Topics: Adult; Antidepressive Agents; Benzodiazepines; Dentate Gyrus; Female; Fluoxetine; Humans; Immunohist | 2014 |
Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Drug A | 2015 |
Mitochondrial dysfunction bridges negative affective disorders and cardiomyopathy in socially isolated rats: Pros and cons of fluoxetine.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Cardiomyopathies; Depression; Disease Models, Animal; | 2017 |
A polymorphism of the GTP-cyclohydrolase I feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants.
Topics: Adult; Antidepressive Agents; Biopterins; Clinical Trials as Topic; Female; Fluoxetine; Genetic Asso | 2011 |
Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cell Count; Dependovirus; Disease Models, Animal; | 2010 |
An affective disorder in zebrafish with mutation of the glucocorticoid receptor.
Topics: Analysis of Variance; Animals; Animals, Genetically Modified; Anti-Anxiety Agents; Arginine; Brain; | 2013 |
Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Female; Fluoxetine; Humans; Male; | 2007 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
Topics: Adult; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic | 2008 |
The treatment of premenstrual syndrome--forward into the past.
Topics: Adult; Female; Fluoxetine; Humans; Mood Disorders; Premenstrual Syndrome; Serotonin | 1995 |
Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Fluoxetine; Humans; Male; Meth | 1995 |
Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Collagen; Female; Fluoxetine; Huma | 1996 |
Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.
Topics: Adult; Analgesics, Opioid; Antidepressive Agents, Second-Generation; Drug Interactions; Female; Fluo | 1996 |
Birth outcomes in pregnant women taking fluoxetine.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Infant, Newborn; Infant, Newborn, Diseases; | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Dis | 1997 |
Treatment of pathological affect: variability of response for laughter and crying.
Topics: Aged; Crying; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Laughter; Male; Middle A | 2000 |
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.
Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Dose-Response Relationship, Drug; Female | 2001 |
Mood disorders in children and adolescents: psychopharmacological treatment.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combi | 2001 |
The ethics of the broader usage of Prozac: social choice or social bias?
Topics: Behavior Control; Depression; Female; Fluoxetine; Humans; Mood Disorders; Risk Assessment; Self Conc | 1995 |